Skip to main content
An official website of the United States government

Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

Major Programs

Staff List

Photo Name, Email, Phone Room Group(s)/Office
Asefa, Wosene
 wosene.asefa@nih.gov
240-276-6422 		5E504 Program Support Assistant | Chemopreventive Agent Development
Biswas, Kajal, Ph.D.
 kajal.biswas2@nih.gov
240-276-5614 		5E540 Program Officer | Chemopreventive Agent Development
Cholewa, Brian, Ph.D.
 brian.cholewa@nih.gov
240-276-7545 		5E446 Deputy Chief | Chemopreventive Agent Development
Clifford, John, Ph.D.
 john.clifford@nih.gov
202-235-4482 		5E430 Program Officer | Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D.
 vignesh.gunasekharan@nih.gov
240-276-5814 		5E438 Program Officer | Chemopreventive Agent Development
Mohammed, Altaf, Ph.D.
 altaf.mohammed@nih.gov
240-276-6082 		5E542 Deputy Chief | Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S.
 ancy.nalli@nih.gov
202-276-5265 		5E536 Program Officer | Chemopreventive Agent Development
Sei, Shizuko, M.D.
 shizuko.sei@nih.gov
240-276-5005 		5E452 Co-Chief | Chemopreventive Agent Development
Shoemaker, Robert, Ph.D.
 robert.shoemaker@nih.gov
240-276-7077 		5E454 Co-Chief | Chemopreventive Agent Development
Acting Chief | Nutritional Science
Vlad, Anda, M.D., Ph.D.
 anda.vlad@nih.gov
240-276-6422 		5E538 Program Officer | Chemopreventive Agent Development

Grants

PI Name PI Organization Title Grant Number Program Official
Clapper, Margie L.

Research Inst Of Fox Chase Can Ctr
United States

 Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center 5U54CA272686-04
Clare, Susan E.

Northwestern University At Chicago
United States

 Lipid-initiated epigenetic reprogramming of the breast to a neural phenotype 1R21CA288676-01A1
Cocucci, Emanuele

Ohio State University
United States

 A SYNTHETIC BIOMARKER TO UNIVERSALLY ASSESS THE RELATIVE CONTRIBUTION OF HEATHY AND CANCEROUS TISSUE TO CIRCULATING EV POOL 5R01CA270251-03 Matthew Young, Ph.D.
Cohen, Lorenzo

University Of Tx Md Anderson Can Ctr
United States

 Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery 5R01CA272565-03 Brennan Streck, Ph.D., RN, M.P.H.
Cohn, Barbara A

Public Health Institute
United States

 Discriminatory Mechanisms in Early-Onset and Lethal Prostate Cancer 5R01CA264519-05 Howard L. Parnes, M.D.
Cook, Linda S

University Of Colorado Denver
United States

 NOT-CA-24-111 Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN) 3UG1CA286941-02S1 Elyse LeeVan, M.D., M.P.H.
Cremer, Miriam

Cleveland Clinic Lerner Com-Cwru
United States

 Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE) 5R01CA266059-04 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Crowder, Sylvia

H. Lee Moffitt Cancer Ctr & Res Inst
United States

 The MIND-BC Study: MIND diet for Breast cancer Cognition 1R01CA299480-01 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Curtis, Amarinthia E

Spartanburg Regional Medical Center
United States

 Upstate Carolina Consortium - Community Oncology Research Program 3UG1CA239762-06S1 Vanessa A. White, M.P.H.
Curtius, Kathleen M.

University Of California, San Diego
United States

 Multiscale modeling of spatiotemporal evolution in Barrett's esophagus 5R01CA270235-03 Asad Umar, D.V.M., Ph.D.
Czerniak, Bogdan A

University Of Tx Md Anderson Can Ctr
United States

 Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. 1P01CA296429-01A1 Howard L. Parnes, M.D.
Damaj, M. Imad

Virginia Commonwealth University
United States

 Inhibition of NLRP3 inflammasome for the treatment of Chemotherapy-induced peripheral neuropathy 1R21CA296516-01 Rachel Altshuler, Ph.D.
Damaj, M. Imad

Virginia Commonwealth University
United States

 Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms 5R01CA272147-03 Rachel Altshuler, Ph.D.
Daniel-Macdougall, Carrie

University Of Tx Md Anderson Can Ctr
United States

 Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma 5R01CA291965-02 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Dashwood, Roderick H

Texas A&M University Health Science Ctr
United States

 Immunoepigenetic targeting of MHC regulators in FAP 5R01CA257559-03